Skip to main content
Novartis
language-selector-globe
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Albania | English
Albania | Shqip
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Albania | English
Albania | Shqip
Argentina | Español
Australia | English
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
United States | English
    • About 
      • Novartis in Ireland 
      • Country Leadership Team 
      • Contact 
      Novartis office
      About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Education and Awareness 
      • Adverse Event Reporting 
      • Novartis Societal Impact 
      Happy family outdoors
      Patients and Caregivers
    • Healthcare Professionals 
      • Healthcare professional country resource 
      • Adverse Event Reporting 
      • Novartis Clinical Trials 
      • Novartis Ireland travel and Expenses Guidance 
      Healthcare professional talking with patient.
      Healthcare Professionals
    • ESG 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
      • Ethics, Risk and Compliance 
      • Environmental Sustainability 
      As a global company, Novartis has a great responsibility and an even greater opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.
      ESG
    • News 
      • News Archive 
      • Stories 
      • Contacts 
      Working on a Tablet
      News
    • Careers 
      • Career Search 
      • Working in Novartis Ireland 
      • Learning and Development 
      • Early Talent 
      • How We Work 
      • Well-being 
      • Diversity & Inclusion 
      • Awards and Recognition 
      Careers
      Careers
    • Investors
      • Financial Data 
    • Coronavirus 
      covid 10 grey image_0_0
      Coronavirus
    Home

Stories

Story Navigation
  • All Topics
  • Education & Awareness
  • Corporate
  • People and Culture
icon
  • The Untold Stories of Urticaria
    Education Awareness
    Oct 1, 2026

    Chronic Spontaneous Urticaria in Ireland: what interim patient survey findings reveal

    For World Urticaria Day on 1 October, Novartis Ireland is sharing early findings from an ongoing survey of people living with Chronic Spontaneous Urticaria (CSU) in Ireland.

    Chronic Spontaneous Urticaria (CSU), also known as chronic hives, is a long-term condition that causes recurring itching, hives and swelling without a known external trigger. CSU affects more than the skin: it can disrupt sleep, wellbeing, work, family life and social activities.

    The 2026 World Urticaria Day theme, “Take Back Control – From Itch to Understanding”, calls for greater recognition of the lived experience of urticaria and the importance of listening to patients. Interim findings from an ongoing survey in Ireland provide an early picture of how CSU affects patients’ daily lives, work and use of healthcare services.

    How does CSU affect work and healthcare services in Ireland?

    CSU affects people’s ability to work: 41% of respondents have taken time off because of the condition. Among those affected, the average time missed is 16 working days per year, demonstrating the substantial impact of CSU on employment and productivity.

    CSU also places a significant burden on healthcare services. More than half of respondents (54%) have attended an Emergency Department because of CSU, while 64% receive most of their care through the public hospital system. In addition, 31% of patients need specialist appointments two to three times each year, reflecting the condition’s ongoing healthcare burden.

    On reviewing results, Dr Niall Conlon, Consultant Immunologist, St. James's Hospital and Trinity College Dublin, commented:

    “These interim findings highlight that CSU is far more than an intermittent skin condition. The high levels of itching, fatigue and sleep disturbance reported by patients can have a profound effect on day-to-day functioning, wellbeing and productivity. It is particularly striking that over a third of respondents are not fully satisfied with their current treatment, reinforcing the need to continue improving care and outcomes for people living with CSU. We need to do better. I encourage people living with this significant disorder to take part in the survey so that we can build a clearer understanding of their experiences and unmet needs”

    What is the biggest unmet need for people living with CSU?

    Incomplete symptom control is the biggest unmet need for people living with Chronic Spontaneous Urticaria. Among respondents who are not satisfied with their treatment, almost half (47%) say it provides only partial relief, 40% report no meaningful symptom relief, and one-third say their treatment does not improve their quality of life.

    How does Chronic Spontaneous Urticaria affect daily life?

    CSU is much more than a skin condition. Based on 39 responses collected so far, the provisional results show that 74% of respondents say CSU has a significant or severe impact on their daily lives. The most commonly reported symptoms are itching and discomfort (82%), hives or wheals (79%), fatigue and exhaustion (67%), sleep problems (54%), and angioedema—swelling beneath the skin—(49%).

    The interim Irish survey findings also show a substantial emotional and practical burden. Six in ten respondents (61%) report a major impact on their mental and emotional wellbeing. More than half (54%) report a major impact on work or education, family responsibilities, and social life. In addition, 38% avoid social activities and 31% say they struggle to maintain social contact.

    How long does it take to receive a CSU diagnosis in Ireland?

    For many survey participants, the journey to a confirmed CSU diagnosis is long. Respondents report an average of 39 months from first symptoms to diagnosis and 19 months from first seeking medical help to receiving a confirmed diagnosis. Almost half (49%) say they were initially told they had an allergy, and respondents saw an average of four doctors before their diagnosis was confirmed.

    Who can take part in the Irish chronic urticaria survey?

    The Irish chronic urticaria survey remains open and adults aged 18 or over who have received a diagnosis of Chronic Spontaneous Urticaria (CSU) or Chronic Inducible Urticaria (CIndU) are invited to take part. The survey takes approximately 15 minutes, and results will be reported in anonymised, aggregated form.

    Please click here to complete the survey

    This data is based on interim data (39 respondents) collected from a CSU online patient survey conducted by Ipsos, which is supported by Novartis Ireland Ltd. Percentages are averages. A Shared Canvas: The Untold Stories of Urticaria is a depiction of CSU by artist Valentina Vittorio: Instagram this_is_velentina. IE 11803589. September 2026.

    Education Awareness
  • tcd-student-visit
    Education Awareness
    Mar 3, 2025

    Novartis Dublin and the Corporate ERC team welcomed 70+ Trinity College Dublin students

    Education Awareness
  • Rosie McCormack's painting at the art of MS
    Education Awareness
    Oct 28, 2022

    The Art of MS - Symptoms Under the Spotlight exhibition

    Education Awareness
  • photo of people at the launch of the #invisible nation campaign
    Education Awareness
    Oct 28, 2022

    #InvisibleNation campaign launch

    Education Awareness
  • photo of attendees at the societial cost of ms report
    Education Awareness
    Oct 28, 2022

    Launch of the Societal Cost of MS

    Education Awareness
  • Group photo of people at heart of our city launch
    Education Awareness
    Aug 11, 2022

    Heart of Our City initiative improves health for D8 residents

    Education Awareness
  • Blurry image of Anne Doyle at launch of AMD awareness week
    Education Awareness
    Mar 17, 2022

    What do you know about AMD?

    Education Awareness
  • Photo of Novartis Dublin office lit up for rare disease day
    Education Awareness
    Mar 17, 2022

    Novartis LIGHTS UP for Rare Disease Day 2021

    Education Awareness
  • Photo of Evanne Ni Chullinn looking into mirrors
    Education Awareness
    Mar 17, 2022

    Novartis launches new campaign with RTÉ’s Evanne Ni Chuilinn calling on migraine sufferers to #TameYourMigraine

    Education Awareness
  • Image of woman holding her head with pain
    Education Awareness
    Mar 17, 2022

    Majority of Migraine Sufferers Report Experiencing More Frequent and Severe Migraines During Pandemic

    Education Awareness
  • Image of work space
    Education Awareness
    Mar 17, 2022

    MS Ireland and Novartis launch video series to support the wellbeing of those living with multiple sclerosis (MS) during Covid-19 pandemic

    Education Awareness
  • Elderly couple looking at papers
    Education Awareness
    Mar 17, 2022

    ‘We’ll See You’ Campaign - Urges Irish Public to Keep Eye Care Appointments and Be Vigilant for Signs of Age-Related Macular Degeneration

    Education Awareness

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • › Next page

Novartis Ireland

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Stories
Other Novartis Websites
  • Healthcare Professional Resources
  • Global site
Footer Bottom
© 2026 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
Site intended for audiences in Ireland IE417033 March 24